Citation 163284

HALL,IH: LIOU,YF: OKANO,M: LEE,KH:. (1982). ANTITUMOR AGENTS 46: IN VITRO EFFECTS OF ESTERS OF BRUSATOL,BISBRUSATOL,AND RELATED COMPOUNDS ON NUCLEIC ACID PROTEIN SYNTHESIS OF P-388 LYMPHOCYTIC LEUKEMIA CELLS.. 71()

Citation Details

Title	ANTITUMOR AGENTS 46: IN VITRO EFFECTS OF ESTERS OF BRUSATOL,BISBRUSATOL,AND RELATED COMPOUNDS ON NUCLEIC ACID PROTEIN SYNTHESIS OF P-388 LYMPHOCYTIC LEUKEMIA CELLS.
Authors	HALL,IH: LIOU,YF: OKANO,M: LEE,KH:
Year	1982
Volume	71
Issue

Summary

Year: 1982

Journal: Unknown

Organisms and Their Experiments (19)

Unknown organism

Experiment #	Pharmacology Type	Worktypes	Compound	Results
1	DNA POLYMERASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUCEOSIDE A	WEAK ACTIVITY
2	FORMIC ACID INCORPORATION INTO PURINES INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUCEOSIDE A	WEAK ACTIVITY
3	DIHYDROFOLATE REDUCTASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUCEOSIDE A	ACTIVE
4	PROTEIN SYNTHESIS INHIBITION DURING ELONGATION PROCESS	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUCEOSIDE A	ACTIVE
5	SUCCINATE DEHYDROGENASE INHIBITION(STATE 4)	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUCEOSIDE A	WEAK ACTIVITY
6	SUCCINATE DEHYDROGENASE INHIBITION(STATE 3)	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUCEOSIDE A	INACTIVE
7	ALPHA-KETOGLUTARATE DEHYDROGENASE INHIBITION(STATE 4)	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUCEOSIDE A	WEAK ACTIVITY
8	ALPHA-KETOGLUTARATE DEHYDROGENASE INHIBITION(STATE 3)	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUCEOSIDE A	INACTIVE
9	ANTITUMOR ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VIVOSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODEANTICANCER AND/OR CYTOTOXICITY MARKER CODE	BRUCEOSIDE A	INACTIVE
10	DNA SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUCEOSIDE A	WEAK ACTIVITY
11	RNA SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUCEOSIDE A	WEAK ACTIVITY
12	PROTEIN SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUCEOSIDE A	ACTIVE

Unknown organism

Experiment #	Pharmacology Type	Worktypes	Compound	Results
1	DNA POLYMERASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUSATOL	ACTIVE
2	FORMIC ACID INCORPORATION INTO PURINES INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUSATOL	ACTIVE
3	DIHYDROFOLATE REDUCTASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUSATOL	ACTIVE
4	PROTEIN SYNTHESIS INHIBITION DURING ELONGATION PROCESS	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUSATOL	ACTIVE
5	SUCCINATE DEHYDROGENASE INHIBITION(STATE 4)	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUSATOL	WEAK ACTIVITY
6	SUCCINATE DEHYDROGENASE INHIBITION(STATE 3)	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUSATOL	INACTIVE
7	ALPHA-KETOGLUTARATE DEHYDROGENASE INHIBITION(STATE 4)	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUSATOL	WEAK ACTIVITY
8	ALPHA-KETOGLUTARATE DEHYDROGENASE INHIBITION(STATE 3)	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUSATOL	WEAK ACTIVITY
9	ANTITUMOR ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VIVOSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODEANTICANCER AND/OR CYTOTOXICITY MARKER CODE	BRUSATOL	ACTIVE
10	DNA SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUSATOL	ACTIVE
11	RNA SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUSATOL	ACTIVE
12	PROTEIN SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUSATOL	ACTIVE

Unknown organism

Experiment #	Pharmacology Type	Worktypes	Compound	Results
1	DNA POLYMERASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUCEANTIN	ACTIVE
2	FORMIC ACID INCORPORATION INTO PURINES INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUCEANTIN	ACTIVE
3	DIHYDROFOLATE REDUCTASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUCEANTIN	ACTIVE
4	PROTEIN SYNTHESIS INHIBITION DURING ELONGATION PROCESS	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUCEANTIN	WEAK ACTIVITY
5	SUCCINATE DEHYDROGENASE INHIBITION(STATE 4)	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUCEANTIN	WEAK ACTIVITY
6	SUCCINATE DEHYDROGENASE INHIBITION(STATE 3)	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUCEANTIN	WEAK ACTIVITY
7	ALPHA-KETOGLUTARATE DEHYDROGENASE INHIBITION(STATE 4)	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUCEANTIN	WEAK ACTIVITY
8	ALPHA-KETOGLUTARATE DEHYDROGENASE INHIBITION(STATE 3)	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUCEANTIN	WEAK ACTIVITY
9	ANTITUMOR ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VIVOSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODEANTICANCER AND/OR CYTOTOXICITY MARKER CODE	BRUCEANTIN	ACTIVE
10	DNA SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUCEANTIN	ACTIVE
11	RNA SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUCEANTIN	ACTIVE
12	PROTEIN SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUCEANTIN	ACTIVE

Unknown organism

Experiment #	Pharmacology Type	Worktypes	Compound	Results
1	DNA POLYMERASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUSATOL TRIACETATE	WEAK ACTIVITY
2	FORMIC ACID INCORPORATION INTO PURINES INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUSATOL TRIACETATE	INACTIVE
3	DIHYDROFOLATE REDUCTASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUSATOL TRIACETATE	ACTIVE
4	PROTEIN SYNTHESIS INHIBITION DURING ELONGATION PROCESS	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUSATOL TRIACETATE	ACTIVE
5	SUCCINATE DEHYDROGENASE INHIBITION(STATE 4)	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUSATOL TRIACETATE	WEAK ACTIVITY
6	SUCCINATE DEHYDROGENASE INHIBITION(STATE 3)	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUSATOL TRIACETATE	INACTIVE
7	ALPHA-KETOGLUTARATE DEHYDROGENASE INHIBITION(STATE 4)	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUSATOL TRIACETATE	WEAK ACTIVITY
8	ALPHA-KETOGLUTARATE DEHYDROGENASE INHIBITION(STATE 3)	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUSATOL TRIACETATE	INACTIVE
9	ANTITUMOR ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VIVOSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODEANTICANCER AND/OR CYTOTOXICITY MARKER CODE	BRUSATOL TRIACETATE	INACTIVE
10	DNA SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUSATOL TRIACETATE	INACTIVE
11	RNA SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUSATOL TRIACETATE	INACTIVE
12	PROTEIN SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUSATOL TRIACETATE	INACTIVE

Unknown organism

Experiment #	Pharmacology Type	Worktypes	Compound	Results
1	DNA POLYMERASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUCEOLIDE	WEAK ACTIVITY
2	FORMIC ACID INCORPORATION INTO PURINES INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUCEOLIDE	WEAK ACTIVITY
3	DIHYDROFOLATE REDUCTASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUCEOLIDE	WEAK ACTIVITY
4	PROTEIN SYNTHESIS INHIBITION DURING ELONGATION PROCESS	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUCEOLIDE	WEAK ACTIVITY
5	SUCCINATE DEHYDROGENASE INHIBITION(STATE 4)	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUCEOLIDE	WEAK ACTIVITY
6	SUCCINATE DEHYDROGENASE INHIBITION(STATE 3)	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUCEOLIDE	WEAK ACTIVITY
7	ALPHA-KETOGLUTARATE DEHYDROGENASE INHIBITION(STATE 4)	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUCEOLIDE	WEAK ACTIVITY
8	ALPHA-KETOGLUTARATE DEHYDROGENASE INHIBITION(STATE 3)	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUCEOLIDE	WEAK ACTIVITY
9	ANTITUMOR ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VIVOSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODEANTICANCER AND/OR CYTOTOXICITY MARKER CODE	BRUCEOLIDE	ACTIVE
10	DNA SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUCEOLIDE	INACTIVE
11	RNA SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUCEOLIDE	INACTIVE
12	PROTEIN SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUCEOLIDE	ACTIVE

Unknown organism

Experiment #	Pharmacology Type	Worktypes	Compound	Results
1	DNA POLYMERASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUCEOLIDE,3-(3-4-DIMETHYL-2-PENTONYL):	WEAK ACTIVITY
2	FORMIC ACID INCORPORATION INTO PURINES INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUCEOLIDE,3-(3-4-DIMETHYL-2-PENTONYL):	WEAK ACTIVITY
3	DIHYDROFOLATE REDUCTASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUCEOLIDE,3-(3-4-DIMETHYL-2-PENTONYL):	WEAK ACTIVITY
4	PROTEIN SYNTHESIS INHIBITION DURING ELONGATION PROCESS	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUCEOLIDE,3-(3-4-DIMETHYL-2-PENTONYL):	ACTIVE
5	SUCCINATE DEHYDROGENASE INHIBITION(STATE 4)	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUCEOLIDE,3-(3-4-DIMETHYL-2-PENTONYL):	WEAK ACTIVITY
6	SUCCINATE DEHYDROGENASE INHIBITION(STATE 3)	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUCEOLIDE,3-(3-4-DIMETHYL-2-PENTONYL):	WEAK ACTIVITY
7	ALPHA-KETOGLUTARATE DEHYDROGENASE INHIBITION(STATE 4)	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUCEOLIDE,3-(3-4-DIMETHYL-2-PENTONYL):	WEAK ACTIVITY
8	ALPHA-KETOGLUTARATE DEHYDROGENASE INHIBITION(STATE 3)	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUCEOLIDE,3-(3-4-DIMETHYL-2-PENTONYL):	WEAK ACTIVITY
9	ANTITUMOR ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VIVOSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODEANTICANCER AND/OR CYTOTOXICITY MARKER CODE	BRUCEOLIDE,3-(3-4-DIMETHYL-2-PENTONYL):	ACTIVE
10	DNA SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUCEOLIDE,3-(3-4-DIMETHYL-2-PENTONYL):	WEAK ACTIVITY
11	RNA SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUCEOLIDE,3-(3-4-DIMETHYL-2-PENTONYL):	INACTIVE
12	PROTEIN SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUCEOLIDE,3-(3-4-DIMETHYL-2-PENTONYL):	WEAK ACTIVITY

Unknown organism

Experiment #	Pharmacology Type	Worktypes	Compound	Results
1	DNA POLYMERASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUCEANTIN,3-(3-4-DIMETHYL-2-PENTONYL):	ACTIVE
2	FORMIC ACID INCORPORATION INTO PURINES INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUCEANTIN,3-(3-4-DIMETHYL-2-PENTONYL):	ACTIVE
3	DIHYDROFOLATE REDUCTASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUCEANTIN,3-(3-4-DIMETHYL-2-PENTONYL):	WEAK ACTIVITY
4	PROTEIN SYNTHESIS INHIBITION DURING ELONGATION PROCESS	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUCEANTIN,3-(3-4-DIMETHYL-2-PENTONYL):	ACTIVE
5	SUCCINATE DEHYDROGENASE INHIBITION(STATE 4)	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUCEANTIN,3-(3-4-DIMETHYL-2-PENTONYL):	WEAK ACTIVITY
6	ACTIN POLYMERIZATION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUCEANTIN,3-(3-4-DIMETHYL-2-PENTONYL):	WEAK ACTIVITY
7	ALPHA-KETOGLUTARATE DEHYDROGENASE INHIBITION(STATE 4)	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUCEANTIN,3-(3-4-DIMETHYL-2-PENTONYL):	WEAK ACTIVITY
8	ALPHA-KETOGLUTARATE DEHYDROGENASE INHIBITION(STATE 3)	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUCEANTIN,3-(3-4-DIMETHYL-2-PENTONYL):	WEAK ACTIVITY
9	ANTITUMOR ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VIVOSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODEANTICANCER AND/OR CYTOTOXICITY MARKER CODE	BRUCEANTIN,3-(3-4-DIMETHYL-2-PENTONYL):	ACTIVE
10	DNA SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUCEANTIN,3-(3-4-DIMETHYL-2-PENTONYL):	ACTIVE
11	RNA SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUCEANTIN,3-(3-4-DIMETHYL-2-PENTONYL):	WEAK ACTIVITY
12	PROTEIN SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUCEANTIN,3-(3-4-DIMETHYL-2-PENTONYL):	ACTIVE

Unknown organism

Experiment #	Pharmacology Type	Worktypes	Compound	Results
1	DNA POLYMERASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUCEOLIDE,12-ACETYL-3-15-DISENECIOYL:	INACTIVE
2	FORMIC ACID INCORPORATION INTO PURINES INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUCEOLIDE,12-ACETYL-3-15-DISENECIOYL:	INACTIVE
3	DIHYDROFOLATE REDUCTASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUCEOLIDE,12-ACETYL-3-15-DISENECIOYL:	WEAK ACTIVITY
4	PROTEIN SYNTHESIS INHIBITION DURING ELONGATION PROCESS	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUCEOLIDE,12-ACETYL-3-15-DISENECIOYL:	WEAK ACTIVITY
5	SUCCINATE DEHYDROGENASE INHIBITION(STATE 4)	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUCEOLIDE,12-ACETYL-3-15-DISENECIOYL:	INACTIVE
6	SUCCINATE DEHYDROGENASE INHIBITION(STATE 3)	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUCEOLIDE,12-ACETYL-3-15-DISENECIOYL:	WEAK ACTIVITY
7	ALPHA-KETOGLUTARATE DEHYDROGENASE INHIBITION(STATE 4)	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUCEOLIDE,12-ACETYL-3-15-DISENECIOYL:	INACTIVE
8	ALPHA-KETOGLUTARATE DEHYDROGENASE INHIBITION(STATE 3)	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUCEOLIDE,12-ACETYL-3-15-DISENECIOYL:	INACTIVE
9	ANTITUMOR ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VIVOSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODEANTICANCER AND/OR CYTOTOXICITY MARKER CODE	BRUCEOLIDE,12-ACETYL-3-15-DISENECIOYL:	INACTIVE
10	DNA SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUCEOLIDE,12-ACETYL-3-15-DISENECIOYL:	INACTIVE
11	RNA SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUCEOLIDE,12-ACETYL-3-15-DISENECIOYL:	INACTIVE
12	PROTEIN SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUCEOLIDE,12-ACETYL-3-15-DISENECIOYL:	WEAK ACTIVITY

Unknown organism

Experiment #	Pharmacology Type	Worktypes	Compound	Results
1	DNA POLYMERASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUCEOLIDE,3-15-DISENECIOYL:	ACTIVE
2	FORMIC ACID INCORPORATION INTO PURINES INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUCEOLIDE,3-15-DISENECIOYL:	ACTIVE
3	DIHYDROFOLATE REDUCTASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUCEOLIDE,3-15-DISENECIOYL:	ACTIVE
4	PROTEIN SYNTHESIS INHIBITION DURING ELONGATION PROCESS	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUCEOLIDE,3-15-DISENECIOYL:	ACTIVE
5	SUCCINATE DEHYDROGENASE INHIBITION(STATE 4)	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUCEOLIDE,3-15-DISENECIOYL:	WEAK ACTIVITY
6	SUCCINATE DEHYDROGENASE INHIBITION(STATE 3)	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUCEOLIDE,3-15-DISENECIOYL:	WEAK ACTIVITY
7	ALPHA-KETOGLUTARATE DEHYDROGENASE INHIBITION(STATE 4)	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUCEOLIDE,3-15-DISENECIOYL:	WEAK ACTIVITY
8	ALPHA-KETOGLUTARATE DEHYDROGENASE INHIBITION(STATE 3)	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUCEOLIDE,3-15-DISENECIOYL:	WEAK ACTIVITY
9	ANTITUMOR ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VIVOSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODEANTICANCER AND/OR CYTOTOXICITY MARKER CODE	BRUCEOLIDE,3-15-DISENECIOYL:	ACTIVE
10	DNA SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUCEOLIDE,3-15-DISENECIOYL:	ACTIVE
11	RNA SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUCEOLIDE,3-15-DISENECIOYL:	ACTIVE
12	PROTEIN SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUCEOLIDE,3-15-DISENECIOYL:	ACTIVE

Unknown organism

Experiment #	Pharmacology Type	Worktypes	Compound	Results
1	DNA SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUSATOLYL,BIS-12-12'-DIACETYL: SUCCINATE	INACTIVE
2	RNA SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUSATOLYL,BIS-12-12'-DIACETYL: SUCCINATE	WEAK ACTIVITY
3	PROTEIN SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUSATOLYL,BIS-12-12'-DIACETYL: SUCCINATE	WEAK ACTIVITY
4	DNA POLYMERASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUSATOLYL,BIS-12-12'-DIACETYL: SUCCINATE	INACTIVE
5	FORMIC ACID INCORPORATION INTO PURINES INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUSATOLYL,BIS-12-12'-DIACETYL: SUCCINATE	WEAK ACTIVITY
6	DIHYDROFOLATE REDUCTASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUSATOLYL,BIS-12-12'-DIACETYL: SUCCINATE	WEAK ACTIVITY
7	PROTEIN SYNTHESIS INHIBITION DURING ELONGATION PROCESS	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUSATOLYL,BIS-12-12'-DIACETYL: SUCCINATE	WEAK ACTIVITY
8	SUCCINATE DEHYDROGENASE INHIBITION(STATE 4)	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUSATOLYL,BIS-12-12'-DIACETYL: SUCCINATE	WEAK ACTIVITY
9	SUCCINATE DEHYDROGENASE INHIBITION(STATE 3)	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUSATOLYL,BIS-12-12'-DIACETYL: SUCCINATE	INACTIVE
10	ALPHA-KETOGLUTARATE DEHYDROGENASE INHIBITION(STATE 4)	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUSATOLYL,BIS-12-12'-DIACETYL: SUCCINATE	INACTIVE
11	ALPHA-KETOGLUTARATE DEHYDROGENASE INHIBITION(STATE 3)	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUSATOLYL,BIS-12-12'-DIACETYL: SUCCINATE	INACTIVE
12	ANTITUMOR ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VIVOSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODEANTICANCER AND/OR CYTOTOXICITY MARKER CODE	BRUSATOLYL,BIS-12-12'-DIACETYL: SUCCINATE	INACTIVE

Unknown organism

Experiment #	Pharmacology Type	Worktypes	Compound	Results
1	DNA POLYMERASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BISBRUSATOLYL ADIPATE	ACTIVE
2	FORMIC ACID INCORPORATION INTO PURINES INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BISBRUSATOLYL ADIPATE	ACTIVE
3	DIHYDROFOLATE REDUCTASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BISBRUSATOLYL ADIPATE	WEAK ACTIVITY
4	PROTEIN SYNTHESIS INHIBITION DURING ELONGATION PROCESS	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BISBRUSATOLYL ADIPATE	ACTIVE
5	SUCCINATE DEHYDROGENASE INHIBITION(STATE 4)	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BISBRUSATOLYL ADIPATE	WEAK ACTIVITY
6	SUCCINATE DEHYDROGENASE INHIBITION(STATE 3)	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BISBRUSATOLYL ADIPATE	WEAK ACTIVITY
7	ALPHA-KETOGLUTARATE DEHYDROGENASE INHIBITION(STATE 4)	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BISBRUSATOLYL ADIPATE	WEAK ACTIVITY
8	ALPHA-KETOGLUTARATE DEHYDROGENASE INHIBITION(STATE 3)	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BISBRUSATOLYL ADIPATE	WEAK ACTIVITY
9	ANTITUMOR ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VIVOSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODEANTICANCER AND/OR CYTOTOXICITY MARKER CODE	BISBRUSATOLYL ADIPATE	ACTIVE
10	DNA SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BISBRUSATOLYL ADIPATE	ACTIVE
11	RNA SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BISBRUSATOLYL ADIPATE	ACTIVE
12	PROTEIN SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BISBRUSATOLYL ADIPATE	ACTIVE

Unknown organism

Experiment #	Pharmacology Type	Worktypes	Compound	Results
1	DNA POLYMERASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BISBRUSATOLYL GLUTARATE	ACTIVE
2	FORMIC ACID INCORPORATION INTO PURINES INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BISBRUSATOLYL GLUTARATE	ACTIVE
3	DIHYDROFOLATE REDUCTASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BISBRUSATOLYL GLUTARATE	WEAK ACTIVITY
4	PROTEIN SYNTHESIS INHIBITION DURING ELONGATION PROCESS	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BISBRUSATOLYL GLUTARATE	ACTIVE
5	SUCCINATE DEHYDROGENASE INHIBITION(STATE 4)	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BISBRUSATOLYL GLUTARATE	WEAK ACTIVITY
6	SUCCINATE DEHYDROGENASE INHIBITION(STATE 3)	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BISBRUSATOLYL GLUTARATE	WEAK ACTIVITY
7	ALPHA-KETOGLUTARATE DEHYDROGENASE INHIBITION(STATE 4)	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BISBRUSATOLYL GLUTARATE	WEAK ACTIVITY
8	ALPHA-KETOGLUTARATE DEHYDROGENASE INHIBITION(STATE 3)	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BISBRUSATOLYL GLUTARATE	WEAK ACTIVITY
9	ANTITUMOR ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VIVOSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODEANTICANCER AND/OR CYTOTOXICITY MARKER CODE	BISBRUSATOLYL GLUTARATE	ACTIVE
10	DNA SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BISBRUSATOLYL GLUTARATE	ACTIVE
11	RNA SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BISBRUSATOLYL GLUTARATE	WEAK ACTIVITY
12	PROTEIN SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BISBRUSATOLYL GLUTARATE	ACTIVE

Unknown organism

Experiment #	Pharmacology Type	Worktypes	Compound	Results
1	DNA POLYMERASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BISBRUSATOLYL SUCCINATE	WEAK ACTIVITY
2	FORMIC ACID INCORPORATION INTO PURINES INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BISBRUSATOLYL SUCCINATE	ACTIVE
3	DIHYDROFOLATE REDUCTASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BISBRUSATOLYL SUCCINATE	ACTIVE
4	PROTEIN SYNTHESIS INHIBITION DURING ELONGATION PROCESS	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BISBRUSATOLYL SUCCINATE	ACTIVE
5	SUCCINATE DEHYDROGENASE INHIBITION(STATE 4)	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BISBRUSATOLYL SUCCINATE	WEAK ACTIVITY
6	ACTIN POLYMERIZATION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BISBRUSATOLYL SUCCINATE	WEAK ACTIVITY
7	ALPHA-KETOGLUTARATE DEHYDROGENASE INHIBITION(STATE 4)	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BISBRUSATOLYL SUCCINATE	ACTIVE
8	ALPHA-KETOGLUTARATE DEHYDROGENASE INHIBITION(STATE 3)	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BISBRUSATOLYL SUCCINATE	WEAK ACTIVITY
9	ANTITUMOR ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VIVOSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODEANTICANCER AND/OR CYTOTOXICITY MARKER CODE	BISBRUSATOLYL SUCCINATE	ACTIVE
10	DNA SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BISBRUSATOLYL SUCCINATE	ACTIVE
11	RNA SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BISBRUSATOLYL SUCCINATE	ACTIVE
12	PROTEIN SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BISBRUSATOLYL SUCCINATE	ACTIVE

Unknown organism

Experiment #	Pharmacology Type	Worktypes	Compound	Results
1	DNA POLYMERASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BISBRUSATOLYL MALONATE	ACTIVE
2	FORMIC ACID INCORPORATION INTO PURINES INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BISBRUSATOLYL MALONATE	ACTIVE
3	DIHYDROFOLATE REDUCTASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BISBRUSATOLYL MALONATE	ACTIVE
4	PROTEIN SYNTHESIS INHIBITION DURING ELONGATION PROCESS	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BISBRUSATOLYL MALONATE	ACTIVE
5	SUCCINATE DEHYDROGENASE INHIBITION(STATE 4)	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BISBRUSATOLYL MALONATE	WEAK ACTIVITY
6	SUCCINATE DEHYDROGENASE INHIBITION(STATE 3)	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BISBRUSATOLYL MALONATE	WEAK ACTIVITY
7	ALPHA-KETOGLUTARATE DEHYDROGENASE INHIBITION(STATE 4)	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BISBRUSATOLYL MALONATE	WEAK ACTIVITY
8	ALPHA-KETOGLUTARATE DEHYDROGENASE INHIBITION(STATE 3)	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BISBRUSATOLYL MALONATE	WEAK ACTIVITY
9	ANTITUMOR ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VIVOSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODEANTICANCER AND/OR CYTOTOXICITY MARKER CODE	BISBRUSATOLYL MALONATE	ACTIVE
10	DNA SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BISBRUSATOLYL MALONATE	ACTIVE
11	RNA SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BISBRUSATOLYL MALONATE	ACTIVE
12	PROTEIN SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BISBRUSATOLYL MALONATE	ACTIVE

Unknown organism

Experiment #	Pharmacology Type	Worktypes	Compound	Results
1	DNA POLYMERASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUSATOLYL,BIS-DIHYDRO: SUCCINATE	WEAK ACTIVITY
2	FORMIC ACID INCORPORATION INTO PURINES INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUSATOLYL,BIS-DIHYDRO: SUCCINATE	ACTIVE
3	DIHYDROFOLATE REDUCTASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUSATOLYL,BIS-DIHYDRO: SUCCINATE	ACTIVE
4	PROTEIN SYNTHESIS INHIBITION DURING ELONGATION PROCESS	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUSATOLYL,BIS-DIHYDRO: SUCCINATE	ACTIVE
5	SUCCINATE DEHYDROGENASE INHIBITION(STATE 4)	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUSATOLYL,BIS-DIHYDRO: SUCCINATE	WEAK ACTIVITY
6	SUCCINATE DEHYDROGENASE INHIBITION(STATE 3)	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUSATOLYL,BIS-DIHYDRO: SUCCINATE	WEAK ACTIVITY
7	ALPHA-KETOGLUTARATE DEHYDROGENASE INHIBITION(STATE 4)	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUSATOLYL,BIS-DIHYDRO: SUCCINATE	ACTIVE
8	ALPHA-KETOGLUTARATE DEHYDROGENASE INHIBITION(STATE 3)	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUSATOLYL,BIS-DIHYDRO: SUCCINATE	WEAK ACTIVITY
9	ANTITUMOR ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VIVOSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODEANTICANCER AND/OR CYTOTOXICITY MARKER CODE	BRUSATOLYL,BIS-DIHYDRO: SUCCINATE	ACTIVE
10	DNA SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUSATOLYL,BIS-DIHYDRO: SUCCINATE	WEAK ACTIVITY
11	RNA SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUSATOLYL,BIS-DIHYDRO: SUCCINATE	WEAK ACTIVITY
12	PROTEIN SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUSATOLYL,BIS-DIHYDRO: SUCCINATE	WEAK ACTIVITY

Unknown organism

Experiment #	Pharmacology Type	Worktypes	Compound	Results
1	DNA POLYMERASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUSATOLYL,BIS-TETRAHYDRO: SUCCINATE	WEAK ACTIVITY
2	FORMIC ACID INCORPORATION INTO PURINES INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUSATOLYL,BIS-TETRAHYDRO: SUCCINATE	INACTIVE
3	DIHYDROFOLATE REDUCTASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUSATOLYL,BIS-TETRAHYDRO: SUCCINATE	WEAK ACTIVITY
4	PROTEIN SYNTHESIS INHIBITION DURING ELONGATION PROCESS	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUSATOLYL,BIS-TETRAHYDRO: SUCCINATE	WEAK ACTIVITY
5	SUCCINATE DEHYDROGENASE INHIBITION(STATE 4)	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUSATOLYL,BIS-TETRAHYDRO: SUCCINATE	INACTIVE
6	SUCCINATE DEHYDROGENASE INHIBITION(STATE 3)	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUSATOLYL,BIS-TETRAHYDRO: SUCCINATE	WEAK ACTIVITY
7	ALPHA-KETOGLUTARATE DEHYDROGENASE INHIBITION(STATE 4)	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUSATOLYL,BIS-TETRAHYDRO: SUCCINATE	INACTIVE
8	ALPHA-KETOGLUTARATE DEHYDROGENASE INHIBITION(STATE 3)	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUSATOLYL,BIS-TETRAHYDRO: SUCCINATE	INACTIVE
9	ANTITUMOR ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VIVOSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODEANTICANCER AND/OR CYTOTOXICITY MARKER CODE	BRUSATOLYL,BIS-TETRAHYDRO: SUCCINATE	INACTIVE
10	DNA SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUSATOLYL,BIS-TETRAHYDRO: SUCCINATE	INACTIVE
11	RNA SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUSATOLYL,BIS-TETRAHYDRO: SUCCINATE	WEAK ACTIVITY
12	PROTEIN SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUSATOLYL,BIS-TETRAHYDRO: SUCCINATE	WEAK ACTIVITY

Unknown organism

Experiment #	Pharmacology Type	Worktypes	Compound	Results
1	DNA POLYMERASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUSATOL,TETRAHYDRO:	INACTIVE
2	FORMIC ACID INCORPORATION INTO PURINES INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUSATOL,TETRAHYDRO:	INACTIVE
3	DIHYDROFOLATE REDUCTASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUSATOL,TETRAHYDRO:	WEAK ACTIVITY
4	PROTEIN SYNTHESIS INHIBITION DURING ELONGATION PROCESS	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUSATOL,TETRAHYDRO:	WEAK ACTIVITY
5	SUCCINATE DEHYDROGENASE INHIBITION(STATE 4)	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUSATOL,TETRAHYDRO:	WEAK ACTIVITY
6	SUCCINATE DEHYDROGENASE INHIBITION(STATE 3)	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUSATOL,TETRAHYDRO:	WEAK ACTIVITY
7	ALPHA-KETOGLUTARATE DEHYDROGENASE INHIBITION(STATE 4)	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUSATOL,TETRAHYDRO:	WEAK ACTIVITY
8	ALPHA-KETOGLUTARATE DEHYDROGENASE INHIBITION(STATE 3)	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUSATOL,TETRAHYDRO:	WEAK ACTIVITY
9	ANTITUMOR ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VIVOSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODEANTICANCER AND/OR CYTOTOXICITY MARKER CODE	BRUSATOL,TETRAHYDRO:	INACTIVE
10	DNA SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUSATOL,TETRAHYDRO:	WEAK ACTIVITY
11	RNA SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUSATOL,TETRAHYDRO:	INACTIVE
12	PROTEIN SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUSATOL,TETRAHYDRO:	WEAK ACTIVITY

Unknown organism

Experiment #	Pharmacology Type	Worktypes	Compound	Results
1	DNA POLYMERASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUSATOL,DIHYDRO:	WEAK ACTIVITY
2	FORMIC ACID INCORPORATION INTO PURINES INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUSATOL,DIHYDRO:	INACTIVE
3	PROTEIN SYNTHESIS INHIBITION DURING ELONGATION PROCESS	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUSATOL,DIHYDRO:	WEAK ACTIVITY
4	SUCCINATE DEHYDROGENASE INHIBITION(STATE 4)	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUSATOL,DIHYDRO:	WEAK ACTIVITY
5	SUCCINATE DEHYDROGENASE INHIBITION(STATE 3)	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUSATOL,DIHYDRO:	WEAK ACTIVITY
6	ALPHA-KETOGLUTARATE DEHYDROGENASE INHIBITION(STATE 4)	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUSATOL,DIHYDRO:	WEAK ACTIVITY
7	ALPHA-KETOGLUTARATE DEHYDROGENASE INHIBITION(STATE 3)	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUSATOL,DIHYDRO:	WEAK ACTIVITY
8	ANTITUMOR ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VIVOSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODEANTICANCER AND/OR CYTOTOXICITY MARKER CODE	BRUSATOL,DIHYDRO:	ACTIVE
9	DNA SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUSATOL,DIHYDRO:	ACTIVE
10	RNA SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUSATOL,DIHYDRO:	WEAK ACTIVITY
11	PROTEIN SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUSATOL,DIHYDRO:	ACTIVE

Unknown organism

Experiment #	Pharmacology Type	Worktypes	Compound	Results
1	DNA POLYMERASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUSATOL,TETRAHYDRO: 2-DEOXO: 2-HYDROXY: LACTOL	WEAK ACTIVITY
2	FORMIC ACID INCORPORATION INTO PURINES INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUSATOL,TETRAHYDRO: 2-DEOXO: 2-HYDROXY: LACTOL	INACTIVE
3	PROTEIN SYNTHESIS INHIBITION DURING ELONGATION PROCESS	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUSATOL,TETRAHYDRO: 2-DEOXO: 2-HYDROXY: LACTOL	WEAK ACTIVITY
4	SUCCINATE DEHYDROGENASE INHIBITION(STATE 4)	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUSATOL,TETRAHYDRO: 2-DEOXO: 2-HYDROXY: LACTOL	INACTIVE
5	SUCCINATE DEHYDROGENASE INHIBITION(STATE 3)	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUSATOL,TETRAHYDRO: 2-DEOXO: 2-HYDROXY: LACTOL	INACTIVE
6	ALPHA-KETOGLUTARATE DEHYDROGENASE INHIBITION(STATE 4)	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUSATOL,TETRAHYDRO: 2-DEOXO: 2-HYDROXY: LACTOL	INACTIVE
7	ALPHA-KETOGLUTARATE DEHYDROGENASE INHIBITION(STATE 3)	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUSATOL,TETRAHYDRO: 2-DEOXO: 2-HYDROXY: LACTOL	WEAK ACTIVITY
8	ANTITUMOR ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VIVOSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODEANTICANCER AND/OR CYTOTOXICITY MARKER CODE	BRUSATOL,TETRAHYDRO: 2-DEOXO: 2-HYDROXY: LACTOL	INACTIVE
9	DNA SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUSATOL,TETRAHYDRO: 2-DEOXO: 2-HYDROXY: LACTOL	WEAK ACTIVITY
10	RNA SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUSATOL,TETRAHYDRO: 2-DEOXO: 2-HYDROXY: LACTOL	INACTIVE
11	PROTEIN SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROSTRUCTURE-ACTIVITY RELATIONSHIP STUDIES MARKER CODE	BRUSATOL,TETRAHYDRO: 2-DEOXO: 2-HYDROXY: LACTOL	WEAK ACTIVITY

Show SPARQL Queries (1)